bmi for tirzepatide on ingestive behavior in adults with overweight or obesity: a randomized 6-week phase 1 trial Mounjaro (tirzepatide) is a prescription

For the co-lyophilised 20mg blend, a 2ml reconstitution yields 5mg/ml of each compound simultaneously

taking a weight-neutral approach), will help reduce the harmful weight stigma that comes with weight-centric approaches

FDA approval to use GLP-1 drugs for weight loss specifies that those who have a BMI between 27 and 30 must have another weight-related condition, such as those listed above

The human lactation study only evaluated doses up to 1 mg

It's so much easier than driving to a doctor's office thank you

Safety and Side Effects Observed So Far Side effects reported in retatrutide trials were generally consistent with other incretin-based therapies, most commonly involving gastrointestinal symptoms